Show simple item record

dc.contributor.authorMiralpeix Monclús, Cristina
dc.contributor.authorReguera, Ana Cristina
dc.contributor.authorFosch, Anna
dc.contributor.authorCasas, Maria
dc.contributor.authorLillo, Jaume
dc.contributor.authorNavarro, Gemma
dc.contributor.authorFranco, Rafael
dc.contributor.authorCasas, Josefina
dc.contributor.authorAlexander, Stephen P.H.
dc.contributor.authorCasals i Farré, Núria
dc.contributor.authorRodríguez-Rodríguez, Rosalía
dc.date.accessioned2021-03-05T11:06:46Z
dc.date.available2021-03-05T11:06:46Z
dc.date.issued2021-01
dc.identifier.citationMiralpeix, Cristina; Reguera, Ana Cristina; Fosch, Anna [et al.]. Carnitine palmitoyltransferase 1C negatively regulates the endocannabinoid hydrolase ABHD6 in mice, depending on nutritional status. British Journal of Pharmacology, 2021, p. 1-17. Disponible en: <https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.15377>. Fecha de acceso: 5 mar. 2021.ca
dc.identifier.issn1476-5381ca
dc.identifier.urihttp://hdl.handle.net/20.500.12328/2054
dc.description.abstractBackground and Purpose: The enzyme α/β‐hydrolase domain containing 6 (ABHD6), a new member of the endocannabinoid system, is a promising therapeutic target against neuronal‐related diseases. However, how ABHD6 activity is regulated is not known. ABHD6 coexists in protein complexes with the brain‐specific carnitine palmitoyltransferase 1C (CPT1C). CPT1C is involved in neuro‐metabolic functions, depending on brain malonyl–CoA levels. Our aim was to study CPT1C–ABHD6 interaction and determine whether CPT1C is a key regulator of ABHD6 activity depending on nutritional status. Experimental Approach: Co‐immunoprecipitation and FRET assays were used to explore ABHD6 interaction with CPT1C or modified malonyl–CoA‐insensitive or C‐terminal truncated CPT1C forms. Cannabinoid CB1 receptor‐mediated signalling was investigated by determining cAMP levels. A novel highly sensitive fluorescent method was optimized to measure ABHD6 activity in non‐neuronal and neuronal cells and in brain tissues from wild‐type (WT) and CPT1C–KO mice. Key Results: CPT1C interacted with ABHD6 and negatively regulated its hydrolase activity, thereby regulating 2‐AG downstream signalling. Accordingly, brain tissues of CPT1C–KO mice showed increased ABHD6 activity. CPT1C malonyl–CoA sensing was key to the regulatory role on ABHD6 activity and CB1 receptor signalling. Fasting, which attenuates brain malonyl–CoA, significantly increased ABHD6 activity in hypothalamus from WT, but not CPT1C–KO, mice. Conclusions and Implications: Our finding that negative regulation of ABHD6 activity, particularly in the hypothalamus, is sensitive to nutritional status throws new light on the characterization and the importance of the proteins involved as potential targets against diseases affecting the CNS.en
dc.format.extent17ca
dc.language.isoengca
dc.publisherJohn Wiley & Sonsca
dc.relation.ispartofBritish Journal of Pharmacologyca
dc.rights© 2021 The Authors.British Journal of Pharmacologypublished by John Wiley & Sons Ltd on behalf of British Pharmacological Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in anymedium, provided the original work is properly cited and is not used for commercial purposes.ca
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.subject.otherEnzimsca
dc.subject.otherNeuronesca
dc.subject.otherCervellca
dc.subject.otherHipotàlemca
dc.subject.otherProteïnesca
dc.subject.otherRatolinsca
dc.subject.otherNutricióca
dc.subject.otherEnzimases
dc.subject.otherNeuronases
dc.subject.otherCerebroes
dc.subject.otherHipotálamoes
dc.subject.otherProteínases
dc.subject.otherRatoneses
dc.subject.otherNutriciónes
dc.subject.otherEnzymesen
dc.subject.otherNeuronsen
dc.subject.otherBrainen
dc.subject.otherHypothalamusen
dc.subject.otherProteinsen
dc.subject.otherMiceen
dc.subject.otherNutritionen
dc.titleCarnitine palmitoyltransferase 1C negatively regulates the endocannabinoid hydrolase ABHD6 in mice, depending on nutritional statusca
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/2PE/PCI2018-092997/AEIca
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/2PE/SAF2017-83813- C3-3-Rca
dc.subject.udc61ca
dc.identifier.doihttps://dx.doi.org/10.1111/bph.15377ca


Files in this item

 

This item appears in the following Collection(s)

Show simple item record

© 2021 The Authors.British Journal of Pharmacologypublished by John Wiley & Sons Ltd on behalf of British Pharmacological Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in anymedium, provided the original work is properly cited and is not used for commercial purposes.
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc/4.0/
Share on TwitterShare on LinkedinShare on FacebookShare on TelegramShare on WhatsappPrint